[ad_1]
RDIF continues to expand existing agreements with international manufacturing partners to produce the vaccine for more than 500 million people in 2021; Two-dose vaccine required by an individual
The cost of one dose of Sputnik V vaccine for international markets will be less than $ 10. Sputnik V is a two-dose vaccine. Therefore, Sputnik V will be two or more times cheaper than mRNA vaccines with similar levels of efficacy.
The uniqueness of the Russian vaccine lies in the use of two different human adenoviral vectors that allow a stronger and longer-term immune response compared to vaccines that use the same vector for two doses. Sputnik V vaccination will be free for Russian citizens.
RDIF and its partners have launched production of the lyophilized (dry) form of the vaccine, which is stored at +2 to +8 degrees Celsius. This regime allows the distribution of the vaccine in international markets, as well as the expansion of its use in regions with difficult access, including areas with tropical climates. Current agreements between RDIF and major foreign pharmaceutical companies allow Sputnik V vaccine to be produced abroad for 500 million people per year, starting in 2021. Currently, RDIF is considering additional applications from various countries and companies to further increase plus production capacity.
The first international deliveries of the Russian Sputnik V vaccine will be made to customers in January 2021 based on existing partnerships with foreign manufacturers. Those clients who have recently submitted their applications will be able to receive the first batches of the vaccine from March 2021.
Second interim analysis of clinical trial data showed 91.4% efficacy for Sputnik V vaccine on day 28 after the first dose; the efficacy of the vaccine is greater than 95% 42 days after the first dose.
Currently, 40,000 volunteers are participating in the post-registration, double-blind, randomized, placebo-controlled phase III clinical study of the Sputnik V vaccine in Russia, of which more than 22,000 volunteers were vaccinated with the first dose and more than 19,000 volunteers with the first and second doses. There were no unexpected adverse events during the trials. Participant tracking is ongoing.
The Sputnik V vaccine is based on a well-studied human adenoviral vector platform that has been shown to be safe and effective without long-term side effects in more than 250 clinical trials conducted globally over the past two decades.
[ad_2]
